United Therapeutics (NASDAQ:UTHR) Stock: Insider Paul Mahon Sells 8,300 Shares

Key Points

• Executive vice president Paul Mahon sold 8,300 United Therapeutics shares at an average price of $544.30, generating approximately $4.52 million. His remaining ownership fell 15.52% to 45,172 shares.
• UTHR shares declined 1.5% to $533.12, while the company reported quarterly EPS of $7.27, exceeding estimates, despite revenue of $783.3 million falling short of forecasts and declining 1.9% year over year.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $642.69; institutional investors own 94.08% of the company.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $544.30, for a total value of $4,517,690.00. Following the sale, the executive vice president owned 45,172 shares of the company's stock, valued at approximately $24,587,119.60. This represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

United Therapeutics Trading Down 1.5%

NASDAQ UTHR traded down $8.39 on Friday, reaching $533.12. The stock had a trading volume of 654,280 shares, compared to its average volume of 557,193. The business has a 50 day moving average price of $513.75 and a 200 day moving average price of $540.45. United Therapeutics Corporation has a 1 year low of $409.07 and a 1 year high of $609.35. The company has a market capitalization of $22.87 billion, a price-to-earnings ratio of 19.07, a P/E/G ratio of 3.86 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period in the prior year, the firm posted $6.41 EPS. The business's revenue was down 1.9% compared to the same quarter last year. On average, analysts anticipate that United Therapeutics Corporation will post 26.40 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on UTHR. Weiss Ratings downgraded shares of United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research report on Thursday, August 27th. The Goldman Sachs Group restated a "sell" rating and set a $368.00 price target on shares of United Therapeutics in a report on Thursday. Jefferies Financial Group restated a "buy" rating and set a $728.00 price target on shares of United Therapeutics in a report on Wednesday. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of United Therapeutics in a research note on Thursday, October 1st. Finally, JPMorgan Chase & Co. upped their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a report on Thursday, July 23rd. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $642.69.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Pension & Wealth Management Advisors Inc. bought a new stake in United Therapeutics during the third quarter worth approximately $108,000. Davidson Capital Management Inc. lifted its stake in shares of United Therapeutics by 2.7% in the third quarter. Davidson Capital Management Inc. now owns 11,252 shares of the biotechnology company's stock worth $6,097,000 after buying an additional 297 shares during the last quarter. Brindle & Bay Financial Advisors LLC acquired a new stake in shares of United Therapeutics in the third quarter worth $234,000. Signal Advisors Wealth LLC lifted its stake in shares of United Therapeutics by 5.7% in the third quarter. Signal Advisors Wealth LLC now owns 1,950 shares of the biotechnology company's stock worth $1,057,000 after buying an additional 105 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in shares of United Therapeutics in the third quarter worth $417,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company's products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.